<span id="hxjvh"><video id="hxjvh"><ruby id="hxjvh"></ruby></video></span>
<th id="hxjvh"></th>
<span id="hxjvh"><dl id="hxjvh"></dl></span>
<span id="hxjvh"></span> <strike id="hxjvh"><dl id="hxjvh"><cite id="hxjvh"></cite></dl></strike>
<span id="hxjvh"></span>
<span id="hxjvh"></span>
<span id="hxjvh"><dl id="hxjvh"><del id="hxjvh"></del></dl></span>
<span id="hxjvh"></span>
<span id="hxjvh"></span>
<span id="hxjvh"><dl id="hxjvh"></dl></span><span id="hxjvh"><dl id="hxjvh"><ruby id="hxjvh"></ruby></dl></span>
<span id="hxjvh"><dl id="hxjvh"><cite id="hxjvh"></cite></dl></span>

Welcome to Taixing Yangzi Pharm Chemical Co.,Ltd. official website

zzm@yzyyhg.com

+86-523-87671879 , +86-523-87679356 , +86-13905264660

NONACAP Group companies
A professional company that produces pharmaceutical intermediates

NEWS

Committed to providing excellent and reliable products and services

German pharmaceutical and chemical giant Merck considers selling consumer health business

Time:2019-03-22

[China Pharmaceutical Network] Company News] German pharmaceutical and chemical giant Merck announced on the 5th that it is considering selling all or part of its assets in the consumer health sector. Some analysts pointed out that the move is aimed at alleviating the pressure of Merck's internal financial constraints.

In the announcement issued on the same day, Merck said it is also possible to find a strategic partner for the consumer health business. The process of assessing the outlook for this business is still at an early stage.

The German Merck Group has nothing to do with the US pharmaceutical giant Merck. According to the website of Merck in Germany, the group's consumer health department has about 3,800 employees and owns 10 core brands including Bion and Seven Seas in 40 markets around the world. Last year, it created about 860 million euros. $1.02 billion in sales.

Some analysts said that Merck hopes to focus its main expenses on the new anti-cancer drug Bavencio, the first new anti-cancer therapy launched by the group in the past decade, developed by Merck and US pharmaceutical giant Pfizer. In the first half of this year, Bavencio received FDA approval to become the world's first PD-1/PD-L1 immunotherapy approved for the treatment of metastatic Merkel cell carcinoma (mMCC).

Boosted by the latest sale of assets, the share price of Merck's listing in Frankfurt rose nearly 3% in early trading on the 5th.

Original title: German pharmaceutical and chemical giant Merck considers selling consumer health business

(Source: China Securities Journal? China Securities Network (Beijing))

yy4080午夜一级,永久天堂网av手机版,欧美AV专区一中文字,免费中文字幕午夜理论,中文字幕无线码免费